Welcome to our dedicated page for Biogen news (Ticker: BIIB), a resource for investors and traders seeking the latest updates and insights on Biogen stock.
Biogen Inc. (Nasdaq: BIIB) is a pioneering biotechnology company founded in 1978, dedicated to discovering, developing, and delivering innovative therapies for people living with serious neurological and neurodegenerative diseases. With a robust portfolio of medicines, Biogen is a global leader in the treatment of multiple sclerosis (MS) and has introduced the first and only approved treatment for spinal muscular atrophy (SMA). The company is also at the forefront of research for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).
Headquartered in Cambridge, Massachusetts, Biogen operates worldwide with research facilities in Zug, Switzerland, and state-of-the-art manufacturing plants in North Carolina and Denmark. The company employs approximately 7,000 people globally, emphasizing a collaborative and inclusive work environment.
Biogen's significant achievements include the development of revolutionary MS treatments such as Avonex, Plegridy, Tysabri, Tecfidera, and Vumerity. The company also markets Spinraza for SMA and Leqembi for Alzheimer’s disease, in collaboration with partners like Ionis and Eisai respectively. Biogen continues to expand its pipeline with promising candidates currently in various stages of clinical trials.
Recent developments have seen Biogen and Eisai submit a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for monthly maintenance dosing of Leqembi, aimed at treating Alzheimer's disease in its early stages. Furthermore, Biogen published its 2023 Corporate Responsibility Report, highlighting its commitment to sustainable practices and social responsibility across four key pillars.
In addition to its core operations, Biogen collaborates with companies like Delta Flight Products to improve travel experiences for passengers with reduced mobility. This initiative reflects Biogen’s broader mission to enhance the quality of life for individuals facing debilitating conditions.
Biogen's financial health is robust, with strategic mergers and acquisitions like the recent purchase of Human Immunology Biosciences for $1.15 billion, aiming to bolster its immunology pipeline. The company’s comprehensive approach to business involves balancing bold scientific endeavors with prudent financial management to ensure long-term growth and shareholder value.
For more information about Biogen's latest news and updates, visit www.biogen.com.
Eisai and Biogen presented new findings for lecanemab-irmb (LEQEMBI), their Alzheimer's disease treatment, at the CTAD Conference. Three-year continuous treatment data showed significant benefits: 59% of patients with no/low tau accumulation showed improvement or no decline, while 46% of patients with low amyloid levels improved or had no decline on cognitive scales. A new testing method revealed strong correlation between protofibrils and neurodegenerative biomarkers. Long-term safety profile remained consistent with no new concerns, with most ARIA events occurring in the first six months of treatment.
Biogen (BIIB) and Neomorph have announced a research collaboration to develop molecular glue degraders for Alzheimer's, rare neurological, and immunological diseases. The partnership combines Neomorph's molecular glue discovery platform with Biogen's expertise in disease research and drug development. Under the agreement, Neomorph will receive an upfront payment and is eligible for milestone payments totaling up to $1.45 billion, plus potential royalties ranging from mid-single digit to low double-digit percentages. The collaboration aims to identify and validate small molecule therapeutic molecular glue degraders for high-priority targets, with Biogen leading the clinical development and commercialization efforts.
Biogen has appointed Daniel Quirk, MD as Chief Medical Officer and Head of Medical Affairs, effective October 28, 2024. Dr. Quirk will report to Priya Singhal, Head of Development. Previously, he served as Senior Vice President of Worldwide Medical Affairs for Immunology and Neuroscience at Bristol-Myers Squibb, and held leadership positions at Pfizer. Dr. Quirk's background includes medical practice as Associate Chief of Gastroenterology at Thomas Jefferson University Health Systems, with degrees from Brown University (MD), Harvard School of Public Health (MPH), and Wharton School (MBA).
Biogen (NASDAQ: BIIB) announced that Executive Vice President and CFO Michael McDonnell will retire on February 28, 2025. Robin Kramer, current Chief Accounting Officer, will succeed him as CFO. McDonnell, who served since August 2020, led cost structure realignment and strategic acquisitions. Kramer, who joined Biogen in 2018, has overseen key finance functions including Treasury and global procurement. She brings extensive experience from roles at Hertz Global Holdings, Fisher Scientific, and The Gillette Company, and was an audit partner at major accounting firms. The transition will occur over the coming months to ensure continuity in Biogen's financial leadership.
Biogen (BIIB) presented complete results from Phase 2 IGNAZ study of felzartamab in IgA Nephropathy (IgAN) patients. The study demonstrated substantial proteinuria reductions and stable kidney function, with effects lasting over 18 months post-treatment. The trial (n=54) showed approximately 50% reduction in urinary protein:creatinine ratio through month 24. Felzartamab, an investigational anti-CD38 monoclonal antibody, selectively reduced IgA antibody levels while maintaining IgG and IgM levels. The treatment was generally well-tolerated, and the company is planning Phase 3 development.
Biogen (BIIB) announced upcoming presentations at the Clinical Trials on Alzheimer's Disease (CTAD) annual conference in Madrid, Spain (October 29 - November 1). The company will present new scientific findings from its Alzheimer's portfolio, including data on treatment aspects and preclinical Alzheimer's disease research across different racial groups.
Key presentations will focus on lecanemab treatment in clinical practice, the AHEAD 3-45 study design, and AI-derived prognostic covariates. The company will also host a virtual booth exploring tau's role in Alzheimer's disease, featuring an interactive medical education module on knowtau.com.
Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations at the American Society of Nephrology's Kidney Week 2024 in San Diego, California. The presentations will focus on felzartamab, an investigational anti-CD38 monoclonal antibody being developed for rare immune-mediated diseases.
Key highlights include:
- A late-breaking oral presentation featuring final results from the Phase 2 IGNAZ study of felzartamab for IgA nephropathy (IgAN)
- An oral presentation examining felzartamab's impact on key disease-relevant biomarkers
- A poster presentation on felzartamab's mechanisms of action
Biogen is planning to advance felzartamab into Phase 3 development as a potential first-in-class therapeutic for various rare immune-mediated indications.
Biogen Inc. (Nasdaq: BIIB) announced that felzartamab, an investigational anti-CD38 monoclonal antibody, has received Breakthrough Therapy Designation (BTD) from the U.S. FDA for treating late antibody-mediated rejection (AMR) without T-cell mediated rejection in kidney transplant patients. The designation is based on clinical proof of concept data and aims to expedite development and review of drugs for serious conditions with potential for substantial improvement over existing therapies.
Felzartamab is being developed as a potential first-in-class therapeutic for various rare immune-mediated indications. It has previously received BTD and Orphan Drug Designation for primary membranous nephropathy (PMN) and ODD for AMR in kidney transplant recipients. Biogen plans to initiate Phase 3 trials for felzartamab in AMR, IgA nephropathy, and PMN in 2025.
Talkiatry, a leading provider of in-network psychiatric care, has announced a new pathway for postpartum depression (PPD) support. This initiative aims to improve access to care for women experiencing postpartum mental health challenges through virtual appointments with board-certified psychiatrists. The company has launched new educational resources to help women identify PPD symptoms and schedule virtual consultations if needed.
Approximately one in eight new mothers in the United States report experiencing PPD symptoms. Despite its prevalence, access to timely care remains challenging due to a shortage of psychiatrists and long wait times. Talkiatry's telehealth alternative, developed in partnership with Biogen Inc. (Nasdaq: BIIB), aims to address these gaps in maternal mental healthcare.
The new PPD page on Talkiatry's website offers educational information, an online assessment tool, and a scheduling system for appointments with psychiatrists. Talkiatry provides virtual psychiatry and therapy covered by over 60 health insurance plans across 43 states, with new patients seen within days of making an appointment.
Biogen Inc. (Nasdaq: BIIB) has announced positive results from Parts B and C of the Phase 2/3 DEVOTE study, evaluating a higher dose regimen of nusinersen in spinal muscular atrophy (SMA). The study showed benefits in both previously treated and treatment-naïve individuals with infantile-onset or later-onset SMA.
Key findings include:
- The higher dose regimen (50/28 mg) led to significant improvements in motor function compared to a matched sham group
- More rapid reduction in neurofilament light chain (NfL), indicating faster slowing of neurodegeneration
- 67.8% reduction in the risk of death or permanent ventilation compared to sham
- Improvements in motor function for participants transitioning from the approved 12 mg regimen to the higher dose
- Safety profile similar to the approved 12 mg regimen
Biogen plans to submit regulatory applications globally for approval of the nusinersen higher dose regimen.
FAQ
What is the current stock price of Biogen (BIIB)?
What is the market cap of Biogen (BIIB)?
What does Biogen Inc. specialize in?
Where is Biogen headquartered?
What are some of Biogen's key products?
How many employees does Biogen have?
What recent acquisitions has Biogen made?
What are Biogen’s latest research initiatives?
How is Biogen improving travel for people with mobility issues?
What is Biogen’s approach to corporate responsibility?
What is Leqembi and what is its significance?
Where can I find more information about Biogen?
